Cardiomyopathy associated with anti-SARS-CoV-2 vaccination: What do we know?
Author
dc.contributor.author
Parra Lucares, Alfredo Andrés
Author
dc.contributor.author
Toro Cabrera, Luis Alejandro
Author
dc.contributor.author
Weitz Muñoz, Sebastián Ignacio
Author
dc.contributor.author
Ramos Gómez, Angelo Cristóbal
Admission date
dc.date.accessioned
2022-04-28T20:09:21Z
Available date
dc.date.available
2022-04-28T20:09:21Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Viruses 2021, 13, 2493.
es_ES
Identifier
dc.identifier.other
10.3390/v13122493
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/185181
Abstract
dc.description.abstract
The SARS-CoV-2 pandemic has mobilized many efforts worldwide to curb its impact on
morbidity and mortality. Vaccination of the general population has resulted in the administration
of more than 6,700,000,000 doses by the end of October 2021, which is the most effective method to
prevent hospitalization and death. Among the adverse effects described, myocarditis and pericarditis
are low-frequency events (less than 10 per 100,000 people), mainly observed with messenger RNA
vaccines. The mechanisms responsible for these effects have not been specified, considering an
exacerbated and uncontrolled immune response and an autoimmune response against specific
cardiomyocyte proteins. This greater immunogenicity and reactogenicity is clinically manifested in a
differential manner in pediatric patients, adults, and the elderly, determining specific characteristics
of its presentation for each age group. It generally develops as a condition of mild to moderate
severity, whose symptoms and imaging findings are self-limited, resolving favorably in days to weeks
and, exceptionally, reporting deaths associated with this complication. The short- and mediumterm
prognosis is favorable, highlighting the lack of data on long-term evolution, which should be
determined in longer follow-ups.
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
MDPI
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States